| 摘要 |
The present invention relates to a crystalline form of compound (I), 4-{(1S, 2S)-2-[(4-cyclobutylpiperazin-1-yl)carbonyl]-cyclopropyl}-benza mide, (I) pharmaceutical formulations containing said compound and to the use of said active compound in therapy. |
